CTIS2022-501974-21-00进行中（未招募）1 期
A Phase 3, International, Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy, Immunogenicity, and Safety of the 9vHPV Vaccine, a Multivalent L1 Virus-like Particle Vaccine, in the prevention of oral persistent infection with HPV Types 16, 18, 31, 33, 45, 52, or 58 in adult males, 20 to 45 years of age - V503-049
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 6,033
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
- 性别
- Male
入选标准
- •Base Study: Is healthy and is judged to be in good physical health based on medical history and physical examination., Base Study: Is male, from 20 years to 45 years of age inclusive, at the time of signing the informed consent, Base Study: Has provided written informed consent for the study. The participant may also provide consent for future biomedical research. However, the participant may participate in the main study without participating in future biomedical research., Base Study: Agrees to provide study personnel with a primary telephone number as well as an alternate means of contact, if available (such as an alternate telephone number or email) for follow-up purposes., Base Study: Can read, understand, and complete the electronic vaccination report card (eVRC)., Base Study: Has had at least 1 lifetime sexual partner., Extension Study: Participants may continue in the Extension Study if Inclusion Criteria #1 and #4 are still met, and the participants was in either the placebo group in the Base Study or the vaccine group in the Base Study but did not complete the vaccination series., Extension Study: Provides documented informed consent
排除标准
- •Base Study: Has a history of human papillomavirus (HPV)-related anal lesion (anal intraepithelial neoplasia or anal cancer) or HPV related head and neck cancer, Base Study: Has a history or current evidence of any condition, therapy, laboratory abnormality or other circumstance that might confound the results of the study, or interfere with the participant’s participation for the full duration of the study, such that it is not in the best interest of the participant to participate by judgment of investigator., Base Study: Is, at the time of signing informed consent, a user of recreational or illicit drugs or has had a recent history (within the last year) of drug or alcohol abuse or dependence at the discretion of the investigator. Alcohol abusers are defined as those who drink despite recurrent social, interpersonal, and/or legal problems because of alcohol use., Base Study: Has received within 12 months prior to enrollment, is receiving, or plans to receive during the study, the following immunosuppressive therapies: radiation therapy, cyclophosphamide, azathioprine, methotrexate, any chemotherapy, cyclosporin, leflunomide (ARAVA®), TNF-a antagonists, monoclonal antibody therapies (including rituximab [RITUXAN®]), intravenous immunoglobulin (IVIG), anti-lymphocyte sera, or other therapy known to interfere with the immune response. Regarding systemic corticosteroids, a participant will be excluded if he is currently receiving steroid therapy, has recently received such therapy, or has received 2 or more courses of high-dose corticosteroids (=20 mg/day of prednisone [or equivalent] orally or parenterally) lasting at least 1 week in duration in the year prior. Participants using inhaled, nasal, or topical steroids are considered eligible for the study., Base Study: Has received within the 3 months prior to vaccination, is receiving, or plans to receive during the study, any immune globulin product (including RhoGAM™) or blood-derived product other than IVIG., Base Study: Has received inactivated or recombinant vaccines within 14 days prior to vaccination or receipt of live vaccines within 21 days prior to vaccination., Base Study: Is concurrently enrolled in other clinical studies of investigational agents., Base Study: Has previously received a marketed HPV vaccine, or has participated in a clinical trial for any HPV vaccine (receiving either active agent or placebo)., Base Study: Has engaged in sexual activity 48 hours prior to vaccination. Sexual activity is defined as: penile penetrative vaginal intercourse with female partner; penile penetrative or receptive anal intercourse with male or female partner; or oral sex involving any contact between participant's mouth with a female partner's vagina, genital or anal area or male partner's penis or genital or anal area. This also includes any contact between participant's partner's mouth with participant's penis, genital or anal area., Base Study: Is unlikely to adhere to the study procedures, keep appointments, or is planning to permanently relocate from the area prior to the completion of the study or to leave for an extended period when study visits would need to be scheduled., Base Study: Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study., Base Study: Has a history of or clinical evidence at the Day 1 external genital examination of HPV-related external lesion, Ex
研究者
相似试验
进行中（未招募）
1 期
Efficacy, immunogenicity, and safety of the 9vHPV vaccine in adult males 20 to 45 years of ageEUCTR2019-003236-23-DEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc6,000
进行中（未招募）
1 期
Efficacy, immunogenicity, and safety of the 9vHPV vaccine in adult males 20 to 45 years of ageEUCTR2019-003236-23-CZMerck Sharp & Dohme Corp.6,000
进行中（未招募）
1 期
Efficacy, immunogenicity, and safety of the 9vHPV vaccine in adult males 20 to 45 years of ageOral persistent infection caused by any of the human papillomavirus types 16, 18, 31, 33, 45, 52, and 58MedDRA version: 20.0Level: LLTClassification code 10006524Term: Buccal cavity papillomaSystem Organ Class: 100000004864EUCTR2019-003236-23-FRMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc6,000
进行中（未招募）
1 期
Efficacy, immunogenicity, and safety of the 9vHPV vaccine in adult males 20 to 45 years of ageOral persistent infection caused by any of the human papillomavirus types 16, 18, 31, 33, 45, 52, and 58MedDRA version: 20.0Level: LLTClassification code 10006524Term: Buccal cavity papillomaSystem Organ Class: 100000004864EUCTR2019-003236-23-ITMERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.6,000
进行中（未招募）
1 期
Efficacy, immunogenicity, and safety of the 9vHPV vaccine in adult males 20 to 45 years of ageOral persistent infection caused by any of the human papillomavirus types 16, 18, 31, 33, 45, 52, and 58MedDRA version: 20.0Level: LLTClassification code 10006524Term: Buccal cavity papillomaSystem Organ Class: 100000004864EUCTR2019-003236-23-BEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc6,000